Marshall Wace, LLP Akero Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 120,674 shares of AKRO stock, worth $3.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,674Holding current value
$3.23 Million% of portfolio
0.0%Shares
11 transactions
Others Institutions Holding AKRO
# of Institutions
192Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$164 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$145 Million2.2% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$140 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$140 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$131 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.24B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...